688468 Stock Overview
Engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Chemclin Diagnostics Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.36 |
| 52 Week High | CN¥10.96 |
| 52 Week Low | CN¥5.28 |
| Beta | -0.037 |
| 1 Month Change | 5.44% |
| 3 Month Change | 36.04% |
| 1 Year Change | -30.30% |
| 3 Year Change | -56.14% |
| 5 Year Change | n/a |
| Change since IPO | -70.49% |
Recent News & Updates
Recent updates
Weak Statutory Earnings May Not Tell The Whole Story For Chemclin Diagnostics (SHSE:688468)
Nov 06
Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings
Sep 28Concerns Surrounding Chemclin Diagnostics' (SHSE:688468) Performance
May 06Little Excitement Around Chemclin Diagnostics Co., Ltd.'s (SHSE:688468) Earnings
Apr 30Chemclin Diagnostics (SHSE:688468) Shareholders Will Want The ROCE Trajectory To Continue
Mar 27Shareholder Returns
| 688468 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -2.6% | -2.8% | -1.2% |
| 1Y | -30.3% | -9.2% | 11.8% |
Return vs Industry: 688468 underperformed the CN Medical Equipment industry which returned -9.2% over the past year.
Return vs Market: 688468 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 688468 volatility | |
|---|---|
| 688468 Average Weekly Movement | 7.8% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688468 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688468's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 695 | n/a | www.chemclin.com |
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company was founded in 2007 and is headquartered in Beijing, China.
Chemclin Diagnostics Co., Ltd. Fundamentals Summary
| 688468 fundamental statistics | |
|---|---|
| Market cap | CN¥2.90b |
| Earnings (TTM) | CN¥139.29m |
| Revenue (TTM) | CN¥443.86m |
20.9x
P/E Ratio6.5x
P/S RatioIs 688468 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688468 income statement (TTM) | |
|---|---|
| Revenue | CN¥443.86m |
| Cost of Revenue | CN¥106.69m |
| Gross Profit | CN¥337.17m |
| Other Expenses | CN¥197.88m |
| Earnings | CN¥139.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 75.96% |
| Net Profit Margin | 31.38% |
| Debt/Equity Ratio | 15.7% |
How did 688468 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield36%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 23:59 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chemclin Diagnostics Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|